+ All Categories
Home > Documents > Eliminated from the body It is the process by which a drug or metabolite is 1Prof.DR.AL SAYED...

Eliminated from the body It is the process by which a drug or metabolite is 1Prof.DR.AL SAYED...

Date post: 03-Jan-2016
Category:
Upload: victoria-doyle
View: 217 times
Download: 0 times
Share this document with a friend
Popular Tags:
66
eliminated from the body It is the process by which a drug or metabolite i 1 Prof.DR.AL SAYED ZAKI- BMC-SAUDIA ARABIA
Transcript

eliminated from the body

It is the process by which

a drug or metabolite is

1Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

o Passive glomerular filtration

o Active tubular secretion in proximal tubules

o Passive tubular reabsorption.

2Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Factors affecting renal excretion:

1-Glomerular filtration rate:

D

• Free • Water soluble • Low molecular weight

Filtered

3Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Acidification of urine• vitamin C • NH4Cl

weak basebase drugs

2-Change in urinary pH

B+

B+

B+B+

B+

B+B+

Ionized

e.g. amphetamine

In AcidicAcidic medium

Excretion

4Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Alkalinization of urine

weak AcidicAcidic drugs

2-Change in urinary pH

Ionized

In AlkalineAlkaline medium

Excretion

e.g. aspirin

A-A-A-A-

A-A-A-

NaHCO3

5Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

oIodides

oRifampicin

oSalicylates

Morphin

e

Tetracycline

Streptomycin

6Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Portal v.

Bile

Ampicillin

Rifampicin

Biliary infection

Morphine

Enterohepatic circulation

7Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

3-Sweat: e.g., rifampicin (red color), vitamin B1.

4-Lungs: e.g., gases and volatile anesthetics.

5-Milk: Morphine Amphetamine Chloramphenicol Oral anticoagulants

8Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

What the drug does to body

9Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

It is the study of the:

Their mechanisms of action

Biological & therapeutic effects of drugs

10Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Physical action :

kaolin adsorbs toxins in diarrhea.

11Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Chemical action :

Hcl

+ NaHCO3

12

Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

RIntracellular

5. Cytotoxic action

Cell membrane

Nucleus

ion

2. selective passage of ions

XY → X +Y

E

Z

4. Metabolic pathway

1. Specific receptors

3. Enzyme

13

Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

E

Rev

Action on enzyme

Irrev

Stimulation Inhibition

Reversible

• short lasting

• e.g: Neostigmine

Cholinesterase

Irreversible

long-lasting (new enzyme synthesis )

e.g:

Organophsphrous compounds

E

E 14

Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

R

Intracellular

Cell membrane

Nucleus

Action on Specific receptors

RR

Bind specifically with a ligand:

• Neurotransmitter

• Drug

• Hormone

Biological response

ligand

15Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

R

Nucleus

Biological response

ligand

Affinity =tendency to bind receptors

Efficacy =

Potency = how much drug is required to elicit a response.

16Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

Agonists

R

ligand

• Affinity

• Efficacy

• Rapid dissociation rate

initiate changes

Antagonists • Affinity

R

ligand

• No efficacy

without initiating change

• slow dissociation rate

• Prevent action of agonist

ligand

17

Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Competitive antagonism

R

antag

Ag

Ag

Ag

R

antag

Ag

Ag

Ag

Non-Competitive antagonism

Displaced by an

excess agonist Not displaced by an

excess agonist 18Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

Partial agonists

Stimulate and block receptors

Affinity

Efficacy (less than full agonist)

Moderate dissociation rate

19Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Inverse agonists •Produce effects opposite to that of agonist

•Benzodiazepines

•Agonists of Bz receptors

• Sedation, • Muscle relaxation • Anxiolytic action

•Inverse agonists of the Bz receptors

•Carbolines

• Convulsions • Anxiety.

20Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

21Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

1 (Age:Newborn infants especially premature are

more susceptible to drugs due to:

Underdevelopment of microsomal enzymes

Low plasma protein and low binding capacity

Reduced excretory function

Immaturity of blood brain barrier 22Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

In infants use:

Clark's formula = adult dose x weight in kg

70

1 (Age:

23Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

•Children require small dose than adults

• In children use

Young's formula = adult dose x Age in years

Age +12

•They may metabolize some drugs more rapid

&so may need high dose of digitalis

1 (Age:

24Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

between 60-70 years

Elderly:

3/4 of adult dose

above 70 years ½the dose.

This is due to :

• Ageing of liver microsomal enzymes

• Underweight

•Reduced renal function

1 (Age:

25Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

2 (Body weight and surface area :

• The bigger the body weight the larger the dose

The increase in weight due to :

Oedema

Or Fat

Is not taken into consideration

26Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

In obese patients :

Dose of fat soluble drugs

Dose of water soluble drugs .

Surface area is more accurate parameter for dose calculation

27Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

2 (Sex:

need smaller dose than

This is due toThis is due to : :

Fat content

Enzyme inhibiting effect of female sex hormones

Enzyme inducing effect of male sex hormone 28Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

During menstruation avoid : salicylates and castor oil.

During pregnancy avoid :

teratogenic drugs,

cathartics and uterine stimulants

During lactation avoid: chloramphenicol,

oral anticoagulantsphenolphthalein

2 (Sex:

29Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

3 (Route of administration:

I.V sublingual & inhalation

S.C I.M. oral >>> >Affect the dose:

I.V dose less than oral.

30Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Magnesium sulphate:

• Orally is purgative

• Rectally is dehydrating agent

• I.V. it is anticonvulsions &

antagonizes Ca++

Affect the Action:

3 (Route of administration:

31Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

4) Drugs intolerance = supersensitivity

= hypersusceptibility:

Exaggerated action to normal dose of a drug

it may be due to:

• Decrease clearance of drug

or

• Upregulation of receptors.

dose

32Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

5(Tolerance:

Failure of response to the usual dose of a drug.

It may be:

1 .Congenital:

a) Racial:

b) Species:

c) Individual variation

2 .Acquired:

33Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

2 .Acquired Tolerance:

e.g:.

• Morphine,

Reversible

It may develop to some actions only & not to all actions

•Ethyl alcohol

• Nitrates, •Ephedrine

34Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Special types of tolerance:

1) Tachyphylaxis e.g:

ephedrine on B.P.

2) Cross tolerance

(tolerance between related drugs)

e.g:

between ethyl alcohol & general anaesthesia.

35Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Variation in drug response may be due to:

3. Number or

function of receptors

R

D

Variation in:

1 .Drug concentration

DD

D2 .Concentration of

endogenous transmitters

RR

36Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

6 (Hypersensitivity (allergic) reaction:

D

Hapten

Immune response

D Does not occur on first exposure

Not dependent on dose

37Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

7) Idiosyncrasy = pharmacogenetics:

Abnormal reaction to drug due to: genetic

or enzyme defect:

o Succinylcholine apnea cholinesterase enzyme

o Malignant hyperthermia with

succinylcholine or halothane

38Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

7) Idiosyncrasy = pharmacogenetics:

o Anaemia & methemoglobinemia

G-6-PD

slow isoniazid acetylatoro Peripheral neuritis with

39Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

8 (Drug dependence:

Habituation :

Emotional or psychological

dependence on the drug

when stopped

Emotional distress

40Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Addiction

Psychic craving for and physical

dependence on the drug

when stopped

severe withdrawal reaction

8 (Drug dependence:

41Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

9 (Pathological State:

Aspirin lowers fever temperature to normal,

but no effect on normal one.

42Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

10 (Cummulation:

Rate of drug administration > elimination

e,g, digitalis and guanethidine

43Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

11 (Emotional State (Placebo effect):

•Placebo are inert dosage forms which produce

their effect psychologically.

•They are used in testing new drugs

44Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

12 (Drug Combinations:

a. Addition or summation:

b. Synergism :

c. Potentiation:

d. Antagonism:

1 (Physiological

2 (Chemical

3 (Pharmacological

45Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Toxicity of Drugs

Adverse (unwanted) drug effects

A) Unpredictable

1- Allergy (hypersensitivity reaction)

2- Idiosyncrasy.

B) Predictable

46Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

B) Predictable:

1- Overdose toxicity.

2- Teratogenic effects

3- Iatrogenic drugs

4- Long-acting sulphonamides can produce

jaundice in premature babies.

47Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

5- Blood dyscrasias by chloramphenicol,

6- Carcinogenic effect, e.g. smoking and radiation.

7- Hepatic toxicity, e.g., halothane.

8- Nephrotoxicity by: sulphonamides, aminoglycosides, phenacetin.

9- Nerve damage, e.g.: streptomycin can produce 8th cranial nerve damage

48Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

10 -Secondary effects, e.g:.

prolonged use of broad spectrum antibiotic

• superinfection &

• Vit. B & K deficiency.

49Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

11-Intolerance.

12-Drug dependence and addiction.

13-Drug interactions.

50Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

51Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Therapeutic dose:

the average adult dose required

to produce a therapeutic effect.

52Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Lethal dose:

dose that produces death

Maximal tolerated dose:

largest safe dose that can be taken.

53Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Loading dose :

the dose given at the onset of therapy to

achieve rapid increase in

plasma drug concentration to reach Css

within therapeutic range.

54Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Maintenance dose :

It is the dose needed to keep

the plasma drug concentration constant

at the steady state

i.e. to compensate for drug loss

in between doses.55Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

Therapeutic index :

LD50/ED50

LD50 (median lethal dose): minimum dose that produces death

in 50% of experimental animals.

ED50 (median effective dose):

dose that produces

a certain pharmacological effect

in 50% of experimental animals.

it is measure for safety of drugs

56

Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

57Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

Plasma half life of a drug (t ½):

24

6

12

18

Drug concentration in Plasma

Time

Decline by

one half

=4 hours ?

58Prof.DR.AL SAYED ZAKI-BMC-

SAUDIA ARABIA

Plasma half life of a drug (t ½):

• It depends on drug clearance

• Half-life (t1/2) is important to indicate

the time required to attain steady state

• It is a measure for drug elimination

59Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Types of drug elimination kinetics

First order kinetics:

a constant proportion of drug is

absorbed, metabolized or eliminated

depending on the drug

concentration

60Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Types of drug elimination kinetics

Zero order kinetics:

where a constant number of

moles are absorbed or eliminated

irrespective of the total amount present.

61Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

First order kinetics

Rate of the process

≠α the amount of drug

t ½ is constant

Linear disappearance curve if log dose is used

Zero order kinetics

Rate of the process

the amount of drug

t ½ increases with dose

Non-linear disappearance curve if log dose is used

62Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Methods to prolong duration of action of drugs

11--Delay absorptionDelay absorption

a) add vasoconstriction e.g adrenaline to local anaesthetics.

b) Add oil e.g. vasopressin.

63Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

e) Use of sustained release (SR) or controlled release (CR)

or timed release (TR)

c) Use of suspensions e.g. protamine zinc insulin.

d) S.C pellet implantation e.g. contraceptives

long acting preparations

64Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

3-Decrease metabolism

4-Delay renal excretion:

probenecid to decrease penicillin excretion.

2-Increase protein binding:

e.g. sulfonamides.

e.g. enzyme inhibitors

65Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA

Prof.DR.AL

66

SEE YOU NEXT TIMESEE YOU NEXT TIME


Recommended